New drug cocktail targets Hard-to-Treat cancers
NCT ID NCT06520488
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new drug called HRS-4642 combined with other anti-cancer agents in people with advanced solid tumors that have a KRAS G12D mutation. The trial has two phases: first to find the safest dose, then to see how well the combination works. About 118 adults aged 18-75 with good performance status are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-4642 combined with SHR-A1921, SHR-A1904, or AG
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific KRAS G12D mutation.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the combination may not prove effective or safe. Side effects from the drug combinations are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.